

s.s.d. Bersagli Molecolari

Pizzamiglio S, Cosentino G, Ciniselli CM, De CL, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, et al. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. *Cancer Med* 2022

Bianchi F, Sommariva M, Le Noci V, Camelliti S, Gagliano N, Giussani M, Balsari A, Tagliabue E, Sfondrini L. Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity. *PLoS ONE* 16 (3):e0248789, 2021.

Camelliti S, Le Noci V, Bianchi F, Storti C, Arnaboldi F, Cataldo A, Indino S, Jachetti E, Figini M, Colombo MP, Balsari A, Gagliano N, Tagliabue E Sfondrini L, Sommariva M. Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. *Cancers (Basel)* 13 (16):4081, 2021.

Cosentino G, Plantamura I, Tagliabue E, Iorio MV, Cataldo A. Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. *Cancers (Basel)*. 13 (15):3691, 2021.

Di Modica M, Gargari G, Regondi V, Bonizzi A, Arioli S, Belmonte B, De Cecco L, Fasano E, Bianchi F, Bertolotti A, Tripodo C, Villani L, Corsi F, Guglielmetti S, Balsari A, Triulzi T, Tagliabue E. Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer. *Cancer Res.* 81:2195-2206, 2021.

Fucà G, Ambrosini M, Agnelli L, Brich S, Sgambelluri F, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Cabras A, Zappasodi R, De Santis F, Anichini A, de Braud F, Gianni AM, Di Nicola M. Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. *J Immunother.Cancer* 9 (6):e002240, 2021.

Giussani M, Ciniselli CM, De Cecco L, Lecchi M, Dugo M, Gargiuli C, Mariancini A, Mancinelli E, Cosentino G, Veneroni S, Paolini B, Orlandi R, Gennaro M, Iorio MV, Depretto C, Ferranti C, Sozzi G, Sensi M, Colombo MP, Scaperrotta G, Tagliabue E, Verderio P. Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended. *Cancers (Basel)* 13 (16):4028, 2021.

Iorio MV. Editorial to the Special Issue "MicroRNA Dysregulation in Tumor Occurrence, Progression and Response to Therapy". *Int J Mol Sci.* 22 (4):2156, 2021.

Lam KC, Araya RE, Huang A, Chen Q, Di Modica M, Rodrigues RR, Lopes A, Johnson SB, Schwarz B, Bohrsen E, Cogdill AP, Bosio CM, et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. *Cell* 2021 Oct 14;184(21):5338-56

Le Noci V, Bernardo G, Bianchi F, Tagliabue E, Sommariva M, Sfondrini L. Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression. *Front Cell Dev.Biol.* 19, 732192, 2021

Lecchi M, Verderio P, Cappelletti V, De Santis F, Paolini B, Monica M, Sangaletti S, Pupa SM., Iorio MV, Bianchi G, Gennaro M, Fuca G, De Braud F, Tagliabue E, Di Nicola M. A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis. *Mol Oncol* 15:1345-1357, 2021.

Ligorio F, Zambelli L, Bottiglieri A, Castagnoli L, Zattarin E, Lobefaro R, Ottini A, Vingiani A, Pupa SM, Bianchi G, Capri G, Pruneri G, De Braud F, Vernieri C. Hormone receptor status influences the impact of Body Mass Index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. *Ther.Adv.Med.Oncol* 13, 2021.

Ligorio F, Pellegrini I, Castagnoli L, Vingiani A, Lobefaro R, Zattarin E, Pupa SM, Pruneri G, De Braud F, Vernieri C. Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. *Cancer Letters* 511:77-87, 2021.

McKee AM, Kirkup BM, Madgwick M, Fowler WJ, Price CA, Dreger SA, Ansorge R, Makin KA, Caim S, Le Gall G, Paveley J, Leclaire C, Dalby M, Alcon-Giner C., Andrusaite A, Feng TY, Di Modica M, Triulzi T, Tagliabue E, Milling SWF, Weillbaeher KN, Rutkowski MR, Korcsmaros T, Hall LJ, Robinson SD. Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth. *iScience* 24 (9):103012, 2021.

Morello G., Cancila V., La Rosa M., Germano G., Lecis D., Amodio V., Zanardi F., Iannelli F., Greco D., La Paglia L., Fiannaca A., Urso A. M., Graziano G., Ferrari F., Pupa S. M., et al. T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. *Cancer Immunol Res.* 9 (7):825-837, 2021.

Piccotti F., Rybinska I., Scoccia E., Morasso C., Ricciardi A., Signati L., Triulzi T., Corsi F., Truffi M.. Lipofilling in Breast Oncological Surgery: A Safe Opportunity or Risk for Cancer Recurrence? *Int J Mol Sci.* 22 (7):3737, 2021.

Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, De Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart M, Daidone MG, Pruneri G, Colombo MP, Tagliabue E, Verderio P, Di Cosimo S. Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis. *Clin Cancer Res.*, 2021.

Pupa SM, Ligorio F, Cancila V, Franceschini A, Tripodo C, Vernieri C, Castagnoli L.. HER2 signaling and breast cancer stem cells: The Bridge behind HER2-positive breast cancer aggressiveness and therapy refractoriness. *Cancers* 13:4778, 2021.

Rybinska I, Mangano N, Tagliabue E, Triulzi T. Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences. *Int J Mol Sci.* 22 (7):3775, 2021.

Tagliabue E. Special Issue: Micro- and Macro-Environmental Factors in Solid Cancers. *Cells* 10 (2):247, 2021.

Triulzi T. Special Issue: "Unraveling the Involvement of Adipose Tissue in Breast Cancer Progression". *Int J Mol Sci.* 22 (10):5107, 2021.

Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, et al. Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET). *Clin Cancer Res.* 27:3443-3455, 2021.

Agnolon V, Contato A, Meneghello A, Tagliabue E, Toffoli G, Gion M, Polo F, Fabricio ASC. ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer-patients undergoing therapy with trastuzumab. *Sci Rep* 2020;10:3016.

Bianchi F, Alexiadis S, Camisaschi C, Truni M, Centonze G, Milione M, Balsari A, Tagliabue E, Sfondrini L. TLR3 expression induces apoptosis in human Non-Small-Cell Lung Cancer. *Int J Molec Sci* 2020;21:1440.

Camelliti S, Le Noci V, Bianchi F, Moscheni C, Arnaboldi F, Gagliano N, Balsari A, Garassino MC, Tagliabue E, Sfondrini L, Sommariva M. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. *J Exp.Clin Cancer Res.* 39 (1):236, 2020

Castagnoli L, De Santis F, Volpari T, Vernieri C, Tagliabue E, Di Nicola M, Pupa SM. Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure. *Cells* 2020 Feb 27;9(3):E555.

L. Castagnoli, E. Tagliabue, and S. M. Pupa. Inhibition of the Wnt signalling pathway: an avenue to control breast cancer aggressiveness. *Int J Mol Sci.* 21:E9069, 2020.

Cataldo A, Romero-Cordoba S, Plantamura I, Cosentino G, Hidalgo-Miranda A, Tagliabue E, Iorio MV. MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer. *Cancers (Basel)* 2020 Aug 12;12(8):E2261.

Cosentino G, Romero-Cordoba S, Plantamura I, Cataldo A, Iorio MV. miR-9-Mediated Inhibition of EFEMP1 Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts. *Cells* 9 (9):2143, 2020.

Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, De Azambuja E, Untch M, et al. Early modulation of circulating MicroRNAs levels in HER2-positive Breast Cancer patients treated with Trastuzumab-based neoadjuvant therapy. *Int J Mol Sci* 2020;21(4):1386.

Di Marco T, Bianchi F, Sfondrini L, Todoerti K, Bongarzone I, Maffioli EM, Tedeschi G, Mazzoni M, Pagliardini S, Pellegrini S, Neri A, Anania MC, et al. COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death. *Cancer Lett* 2020 Feb 13;406:106-19.

Majorini MT, Cancila V, Rigoni A, Botti L, Dugo M, Triulzi T, De Cecco L, Fontanella E, Jachetti E, Tagliabue E, Chiodoni C, Tripodo C, et al. Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype. *Cancer Res* 2020;80:2311-24.

Mercatelli R, Triulzi T, Pavone FS, Orlandi R, Cicchi R. Collagen ultrastructural symmetry and its malignant alterations in human breast cancer revealed by Polarization SHG microscopy. *J Biophotonics* 2020;e202000159.

Mocenigo M, Porchetta A, Rossetti M, Brass E, Tonini L, Puzzi L, Tagliabue E, Triulzi T, Marini B, Ricci F, Ippodrino R. Rapid, cost-effective peptide/nucleic acid-based platform for therapeutic antibody monitoring in clinical samples. *ACS Sens.* 5:3109-3115, 2020.

Plantamura I, Cataldo A, Cosentino G, Iorio MV. miR-205 in Breast Cancer: State of the Art. *Int J Mol Sci.* 22:27, 2020.

Romero-Cordoba S, Salido-Guadarrama I, Meneses ME, Cosentino G, Iorio MV, Tagliabue E, Torres N, Sanchez-Tapia M, Bonilla M, Castillo I, Petlascalco B, Tovar AR, Martinez-Carrera D. Mexican *Ganoderma lucidum* extracts decrease lipogenesis modulating transcriptional metabolic networks and gut microbiota in C57BL/6 mice fed with a high-cholesterol diet. *Nutrients*, 13: E38, 2020.

Romero-Cordoba S, Tagliabue E, Triulzi T, Bianchi F. Deep into breast cancer heterogeneity to increase immunotherapeutic effectiveness. *JCO Precision Oncology*, 2020

Rossini A, Giussani M, Ripamonti F, Aiello P, Regondi V, Balsari A, Triulzi T, Tagliabue E. Combined targeting of EGFR and HER2 against prostate cancer stem cells. *Cancer Biol Ther* 2020;21:463-75.

Rybinska I, Agresti R, Trapani A, Tagliabue E, Triulzi T. Adipocytes in Breast Cancer, the Thick and the Thin. *Cells* 2020;9:E560.

Rybinska I, Sandri M, Bianchi F, Orlandi R, De Cecco L, Gasparini P, Campiglio M, Paolini B, Sfondrini L, Tagliabue E, Triulzi T. Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment. *Cells* 2020 Feb 13;9(2):E434.

Schettini F, Sobhani N, Ianza A, Triulzi T, Molteni A, Lazzari MC, Strina C, Milani M, Corona SP, Sirico M, Bernocchi O, Giudici F, et al. Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. *Breast Cancer Res Treat* 2020 Aug 7.

Sommariva M, Le Noci V, Bianchi F, Camelliti S, Balsari A, Tagliabue E, Sfondrini L. The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. *Cell Mol Life Sci* 2020 Jan 23;77:2739-49.

Tiwari S, Triulzi T, Holton S, Regondi V, Paolini B, Tagliabue E, Bhargava R. Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer. *Sci Rep* 2020;10:5442.

Volpari T, De Santis F, Bracken AP, Pupa SM, Buschbeck M, Wegner A, Di Cosimo S, Lisanti MP, Dotti G, Massaia M, Pruneri G, Anichini A, et al. Anticancer innovative therapy: Highlights from the ninth annual meeting. *Cytokine Growth Factor Rev* 2020 Feb;51:1-9.

Agresti R, Triulzi T, Sasso M, Ghirelli C, Aiello P, Rybinska I, Campiglio M, Sfondrini L, Tagliabue E, Bianchi F. Wound healing fluid reflects the inflammatory nature and aggressiveness of Breast Tumors. *Cells* 2019;8:181.

Beltran-Anaya FO, Romero-Cordoba S, Rebollar-Vega R, Arrieta O, Bautista-Pina V, Dominguez-Reyes C, Villegas-Carlos F, Tenorio-Torres A, Alfaro-Riuz L, Jimenez-Morales S, Cedro-Tanda A, Rios-Romero M, et al. Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death. *Mol Oncol* 2019 Jan 16;13:909-27.

Bianchi F, Milione M, Casalini P, Centonze G, Le Noci V, Storti C, Alexiadis S, Truini M, Sozzi G, Pastorino U, Balsari A, Tagliabue E, et al. Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. *Sci Rep* 2019 Oct 3;9(1):14288-50756.

Castagnoli L, Cancila V, Romero-Cordoba SL, Faraci S, Talarico G, Belmonte B, Iorio MV, Volpari T, Chiodoni C, Hidalgo-Miranda A, Tagliabue E, Tripodo C, et al. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. *Oncogene* 2019;38:4047-60.

Castagnoli L, Iorio E, Dugo M, Koschorke A, Faraci S, Canese R, Casalini P, Nanni P, Vernieri C, Di Nicola M, Morelli D, Tagliabue E, et al. Intra-tumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. *J Cell Physiol* 2019;234:1768-79.

Castagnoli L, Ladomery M, Tagliabue E, Pupa SM. The d16HER2 splice variant: a friend or foe of HER2-positive cancers? *Cancers (Basel)* 2019 Jun 28;11(7).

Cosentino G, Plantamura I, Cataldo A, Iorio MV. MicroRNA and oxidative stress interplay in the context of breast cancer pathogenesis. *Int J Mol Sci* 2019 Oct 17;20(20):5143.

Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, De Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Pena L, Daidone MG, Huober J, et al. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. *Eur J Cancer* 2019 Jul 5;118:1-9.

Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, De Azambuja E, de la Pena L, Izquierdo MA, Huober J, Baselga J, Piccart M, et al. Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from the NeoALTTO trial. *Clin Cancer Res* 2019 Feb 27;25:3887-95.

Galli G, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Fuca G, Ganzinelli M, Vitali M, Palmieri D, Tessari A, De Braud F, et al. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. *Lung Cancer* 2019;132:72-8.

Giussani M, Triulzi T, Sozzi G, Tagliabue E. Tumor extracellular matrix remodeling: new perspectives as a circulating tool in the diagnosis and prognosis of solid tumors. *Cells* 2019 Jan 23;8(2).

Iorio MV, Palmieri D. Editorial: from "Junk DNA" to clinically relevant tools for cancer diagnosis, staging, and tailored therapies: the incredible case of Non-Coding RNAs. *Front Oncol* 2019 May 14;9:389.

Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Ladomery M, Vernieri C, De Braud F, et al. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. *Cell Oncol (Dordr)* 2019 Aug 2;42:815-28.

Le Noci V, Sommariva M, Bianchi F, Triulzi T, Tagliabue E, Balsari A, Sfondrini L. Local administration of caloric restriction mimetics to promote the immune control of Lung Metastases. *J Immunol Res* 2019 Jun;2019:2015892.

Pastorino U, Tagliabue E. Non-Human Determinants of Lung Cancer Outcome: A Target for Inhibition of Pro-Metastatic Effect of Surgery, Triggered by Postoperative Bacterial Pneumonia. *J Thorac Oncol* 2019 Dec;14(12):2039-41.

Romero-Cordoba S, Meneghini E, Sant M, Iorio MV, Sfondrini L, Paolini B, Agresti R, Tagliabue E, Bianchi F. Decoding immune heterogeneity of Triple Negative Breast Cancer and its association with systemic inflammation. *Cancers (Basel)* 2019 Jun 28;11(7).

Vernieri C, Pusceddu S, Fuca G, Indelicato P, Centonze G, Castagnoli L, Ferrari E, Ajazi A, Pupa S, Casola S, Foiani M, Mazzaferro V, et al. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). *Int J Cancer* 2019;144:1704-12.

Vernieri C, Signorelli D, Galli G, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Brogginini M, Hollander L, Gallucci R, et al. Exploiting Fasting-mimicking Diet and METformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. *Clin Lung Cancer* 2019;20(3):-e413.

Volpi CC, Pietrantonio F, Gloghini A, Fuca G, Giordano S, Corso S, Pruneri G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, et al. The landscape of d16HER2 splice variant expression across HER2-positive cancers. *Sci Rep* 2019;9(1):3545.